Rhinitis Management
Intranasal corticosteroids are the first-line treatment for patients with moderate to severe or persistent rhinitis, while second-generation oral antihistamines or intranasal antihistamines are appropriate for mild intermittent symptoms. 1, 2
Initial Classification and Treatment Selection
The management approach depends on distinguishing allergic from nonallergic rhinitis and assessing symptom severity:
For Allergic Rhinitis
Mild intermittent symptoms (< 4 days/week or < 4 weeks/year):
- Start with a second-generation oral antihistamine (cetirizine, fexofenadine, desloratadine, or loratadine) OR an intranasal antihistamine (azelastine or olopatadine) 2
- These agents effectively control sneezing, itching, and rhinorrhea 1, 2
Moderate to severe or persistent symptoms (> 4 days/week and > 4 weeks/year):
- Initiate intranasal corticosteroid monotherapy (fluticasone, mometasone, budesonide, or triamcinolone) as first-line treatment 1, 2
- Intranasal corticosteroids relieve all nasal symptoms including congestion, itching, rhinorrhea, and sneezing, and prevent late-phase allergic responses almost completely 3, 4
- Administer once daily with proper technique: direct spray away from the nasal septum toward the lateral nasal wall to minimize epistaxis and septal perforation risk 1, 5
If intranasal corticosteroid monotherapy is inadequate after 2-4 weeks:
- Add an intranasal antihistamine (azelastine) to the intranasal corticosteroid regimen 5
- This combination provides superior symptom reduction (37.9% improvement) compared to intranasal corticosteroid alone (29.1% improvement) 5
For Nonallergic Rhinitis
The treatment differs significantly from allergic rhinitis:
- Intranasal antihistamines (azelastine or olopatadine) are first-line therapy, either as monotherapy or combined with intranasal corticosteroids 1, 2
- Intranasal corticosteroids may relieve congestion and rhinorrhea in vasomotor rhinitis 1
- Oral nonsedating antihistamines are NOT effective in nonallergic rhinitis and should not be prescribed 1
- For predominant rhinorrhea (gustatory rhinitis), intranasal anticholinergics (ipratropium bromide) are specifically indicated 1, 6
Adjunctive Therapies
Environmental Control Measures
- Implement allergen avoidance even during initial treatment 1
- For severe seasonal allergic rhinitis, advise staying indoors in air-conditioned environments with closed windows and doors 1
Decongestants (Use With Extreme Caution)
Topical decongestants (oxymetazoline, xylometazoline):
- Limit use to maximum 3 days only to prevent rhinitis medicamentosa (rebound congestion) 1, 5
- May be used short-term to reduce severe congestion and allow intranasal corticosteroids to penetrate nasal mucosa effectively 5
- Development of rhinitis medicamentosa is highly variable—can occur within 3 days or fail to develop after 6 weeks 1
Oral decongestants (pseudoephedrine):
- Effective for nasal congestion but cause insomnia, irritability, palpitations, and appetite loss 1
- Use with caution in patients with cardiovascular disease, hyperthyroidism, closed-angle glaucoma, or bladder neck obstruction 1
- Monitor blood pressure in all patients, especially those with controlled hypertension 1
- Avoid in children under 6 years of age due to risk of agitated psychosis, ataxia, hallucinations, and death 1
- Phenylephrine is less effective than pseudoephedrine and has not been well-established as an oral decongestant 1
Nasal Saline Irrigation
- Use 2-3 times daily as cornerstone therapy for rhinitis sicca (dry nasal mucosa) 7
- Provides mechanical moisturization and crust removal 7
Critical Pitfalls to Avoid
Medications that worsen specific rhinitis subtypes:
- Never use topical decongestants beyond 3 days—rhinitis medicamentosa will worsen underlying congestion 1, 7, 5
- Avoid topical decongestants entirely in rhinitis sicca—they further dry nasal mucosa 7
- Do not prescribe oral antihistamines for rhinitis sicca or nonallergic rhinitis—anticholinergic effects worsen dryness and they lack efficacy in nonallergic rhinitis 1, 7
- Avoid prolonged intranasal corticosteroid use without adequate moisturization in rhinitis sicca—can exacerbate dryness 7
Proper intranasal corticosteroid use:
- Ensure daily administration at regular intervals, not as-needed, for optimal effect 5
- Monitor nasal septum periodically for mucosal erosions when using intranasal corticosteroids, especially in rhinitis sicca 7
- Use lowest effective dose if inflammation requires treatment in dry nasal conditions 7
Special considerations for rhinitis medicamentosa:
- Discontinue nasal decongestant sprays and treat with intranasal or systemic corticosteroids 1
Assessment of Treatment Response
Evaluate multiple parameters at follow-up 1:
- Nasal symptoms (congestion, itching, rhinorrhea)
- Physical signs (turbinate edema)
- Quality of life (sleep quality, work/school performance, driving ability)
- Comorbid conditions (asthma control often improves with rhinitis control) 1
Indications for Allergist/Immunologist Referral
Refer when any of the following occur 1:
- Prolonged manifestations despite treatment
- Complications (otitis media, sinusitis, nasal polyposis)
- Comorbid asthma or chronic sinusitis
- Requirement for systemic corticosteroids
- Symptoms or medication side effects interfering with function or sleep
- Significant quality of life impairment (anosmia, ageusia)
- Treatment ineffectiveness or adverse events
- Rhinitis medicamentosa diagnosis
- Need for allergen identification or immunotherapy consideration
- Multiple costly medications required over prolonged periods 1
Special Populations
Pediatric patients:
- OTC cough and cold medications (antihistamine-decongestant combinations) are not effective in children and have safety concerns 1
- Oral decongestants in children under 6 years carry significant risks including tachyarrhythmias, insomnia, hyperactivity, and even death at recommended doses 1
Infectious rhinitis: